{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(5)"],"submitter":["Zambon A"],"funding":["CliCon S.r.l. Società Benefit","Servier","Maria Cappuccilli and Melania Dovizio of CliCon S.r.l. Società Benefit"],"pubmed_abstract":["<h4>Aims</h4>To compare medication adherence, lipid goal attainment, and healthcare costs between patients receiving a single-pill combination (SPC) vs. a free combination treatment (FCT) of rosuvastatin/ezetimibe (ROS/EZE) in Italy.<h4>Methods and results</h4>Administrative databases of healthcare entities covering ∼7 million individuals were used to identify adults prescribed with ROS/EZE as SPC or FCT between January 2018 and June 2020. Adherence was calculated as the proportion of days covered (PDC) after cohort balancing by propensity score matching. Patients with available LDL cholesterol testing were assessed for the proportion of those who at baseline were above lipid targets recommended by ESC/EAS Guidelines for their cardiovascular risk category and reached the target during foll"],"journal":["European heart journal open"],"pagination":["oeae074"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11416014"],"repository":["biostudies-literature"],"pubmed_title":["A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free combination in Italy."],"pmcid":["PMC11416014"],"pubmed_authors":["Perez de Isla L","Zambon A","Veronesi C","Liberopoulos E","Dovizio M","Degli Esposti L"],"additional_accession":[]},"is_claimable":false,"name":"A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin/ezetimibe as single-pill combination vs. free combination in Italy.","description":"<h4>Aims</h4>To compare medication adherence, lipid goal attainment, and healthcare costs between patients receiving a single-pill combination (SPC) vs. a free combination treatment (FCT) of rosuvastatin/ezetimibe (ROS/EZE) in Italy.<h4>Methods and results</h4>Administrative databases of healthcare entities covering ∼7 million individuals were used to identify adults prescribed with ROS/EZE as SPC or FCT between January 2018 and June 2020. Adherence was calculated as the proportion of days covered (PDC) after cohort balancing by propensity score matching. Patients with available LDL cholesterol testing were assessed for the proportion of those who at baseline were above lipid targets recommended by ESC/EAS Guidelines for their cardiovascular risk category and reached the target during foll","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-07-15T14:44:51.18Z","creation":"2025-04-06T13:20:27.962Z"},"accession":"S-EPMC11416014","cross_references":{"pubmed":["39310723"],"doi":["10.1093/ehjopen/oeae074"]}}